The DOI matches its Crossref record; 356 of the 356 references it cites were found in a registry or an index.
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance
Open accessAbstract
// James A. McCubrey 1 , Linda S. Steelman 1 , William H. Chappell 1 , Stephen L. Abrams 1 , Richard A. Franklin 1 , Giuseppe Montalto 2 , Melchiorre Cervello 3 , Massimo Libra 4 , Saverio Candido 4 , Grazia Malaponte 4 , Maria C. Mazzarino 4 , Paolo Fagone 4 , Ferdinando Nicoletti 4 , Jörg Bäsecke 5 , Sanja Mijatovic 6 , Danijela Maksimovic-Ivanic 6 , Michele Milella 7 , Agostino Tafuri 8 , Francesca Chiarini 9 , Camilla Evangelisti 9 , Lucio Cocco 10 , Alberto M. Martelli 9,10 1 Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University, Greenville, NC, USA 2 Department of Internal Medicine and Specialties, University of Palermo, Palermo, Italy 3 Consiglio Nazionale delle Ricerche, Istituto di Biomedicina e Immunologia Molecolare “Alberto Monroy”, Palermo, Italy 4 Department of Bio-Medical Sciences, University of Catania, Catania, Italy 5 Department of Medicine, University of Göttingen, Göttingen, Germany 6 Department of Immunology, Instititue for Biological Research “Sinisa Stankovic”, University of Belgrade, Belgrade, Serbia 7 Regina Elena National Cancer Institute, Rome, Italy 8 Sapienza, University of Rome, Department of Cellular Biotechnology and Hematology, Rome, Italy 9 Institute of Molecular Genetics, National Research Council-Rizzoli Orthopedic Institute, Bologna, Italy 10 Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy Correspondence: James A. McCubrey, email: // Keywords : Targeted Therapy, Therapy Resistance, Cancer Stem Cells, Raf, Akt, PI3K, mTOR Received : September 12, 2012, Accepted : October 18, 2012, Published : October 20, 2012 Abstract The Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades are often activated by genetic alterations in upstream signaling molecules such as receptor tyrosine kinases (RTK). Targeting these pathways is often complex and can result in pathway activation depending on the presence of upstream mutations (e.g., Raf inhibitors induce Raf activation in cells with wild type (WT) RAF in the presence of mutant, activated RAS ) and rapamycin can induce Akt activation. Targeting with inhibitors directed at two constituents of the same pathway or two different signaling pathways may be a more effective approach. This review will first evaluate potential uses of Raf, MEK, PI3K, Akt and mTOR inhibitors that have been investigated in pre-clinical and clinical investigations and then discuss how cancers can become insensitive to various inhibitors and potential strategies to overcome this resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–356 of 356
Oral treatment for multiple sclerosis
Killestein, J., Rudick, R. A., & Polman, C. H. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70228-9 · Cited by 98
mTOR as a multifunctional therapeutic target in HIV infection
Nicoletti, F., Fagone, P., Meroni, P. L., McCubrey, J. A., & Bendtzen, K. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.05.008 · Cited by 96
Self-citationFalcón, B. L., Barr, S. M., Gokhale, P. C., Chou, J., Fogarty, J., Depeille, P., Miglarese, M. R., Epstein, D. M., & McDonald, D. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3126 · Cited by 95
Rao, R. D., Mladek, A. C., Lamont, J. D., Goble, J. M., Erlichman, C., James, C. D., & Sarkaria, J. N. (2005) · Neoplasia · doi:10.1593/neo.05361 · Cited by 95
Schwartz, G. K., Robertson, S., Shen, A., Wang, E., Pace, L., Dials, H. J., Mendelson, D. S., Shannon, P., & Gordon, M. S. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.3513 · Cited by 95
McDaid, H. M., Lopez-Barcons, L. A., Grossman, A., Lia, M., Keller, S. M., Perez-Soler, R., & Horwitz, S. B. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4391 · Cited by 94
Autophagy in the pathogenesis of myelodysplastic syndrome and acute myeloid leukemia
Watson, A., Mortensen, M., & Simon, A. K. (2011) · Cell Cycle · doi:10.4161/cc.10.11.15673 · Cited by 93
Yoon, J., Koo, K.-H., & Choi, K.-Y. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3058 · Cited by 92
Kari, V., Shchebet, A., Neumann, H., & Johnsen, S. A. (2011) · Cell Cycle · doi:10.4161/cc.10.20.17769 · Cited by 92
Lilly, M. B., & Kraft, A. S. (1997) · PubMed · Cited by 91
Chung, E. J., Brown, A. P., Asano, H., Mandler, M. D., Burgan, W. E., Carter, D., Camphausen, K. A., & Citrin, D. E. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2954 · Cited by 91
Tazzari, P. L., Tabellini, G., Ricci, F., Papa, V., Bortul, R., Chiarini, F., Evangelisti, C., Martinelli, G., Bontadini, A., Cocco, L., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2815 · Cited by 91
Self-citationSteelman, L. S., Navolanic, P. M., Chappell, W. H., Abrams, S. L., Wong, E. W. T., Martelli, A. M., Cocco, L., Stivala, F., Libra, M., Nicoletti, F., et al. (2011) · Cell Cycle · doi:10.4161/cc.10.17.17119 · Cited by 89
Self-citationBrognard, J., & Dennis, P. A. (2002) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401054 · Cited by 89
Synergistic Action of a RAF Inhibitor and a Dual PI3K/mTOR Inhibitor in Thyroid Cancer
Jin, N. Y., Jiang, T., Rosen, D. M., Nelkin, B. D., & Ball, D. W. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0933 · Cited by 89
Molecular damage in cancer: an argument for mTOR-driven aging
Blagosklonny, M. V. (2011) · Aging · doi:10.18632/aging.100422 · Cited by 88
Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia
Simioni, C., Neri, L. M., Tabellini, G., Ricci, F., Bressanin, D., Chiarini, F., Evangelisti, C., Cani, A., Tazzari, P. L., Melchionda, F., et al. (2012) · Leukemia · doi:10.1038/leu.2012.136 · Cited by 87
Self-citationUnleashing Chk1 in cancer therapy
Carrassa, L., & Damia, G. L. M. (2011) · Cell Cycle · doi:10.4161/cc.10.13.16398 · Cited by 87
Chomel, J., & Turhan, A. G. (2011) · Oncotarget · doi:10.18632/oncotarget.333 · Cited by 87
Targeting mTOR for the treatment of AML. New agents and new directions
Altman, J. K., Sassano, A., & Platanias, L. C. (2011) · Oncotarget · doi:10.18632/oncotarget.290 · Cited by 87
Legrier, M., Yang, C. H., Yan, H.-G., Lopez-Barcons, L. A., Keller, S. M., Perez-Soler, R., Horwitz, S. B., & McDaid, H. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0702 · Cited by 86
Witkiewicz, A. K., Kline, J., Queenan, M., Brody, J. R., Tsirigos, A., Bilal, E., Pavlides, S., Ertel, A., Sotgia, F., & Lisanti, M. P. (2011) · Cell Cycle · doi:10.4161/cc.10.11.15675 · Cited by 86
Menéndez, J. A., Cufí, S., Oliveras‐Ferraros, C., Martín-Castillo, B., Joven, J., Vellón, L., & Vázquez‐Martín, A. (2011) · Aging · doi:10.18632/aging.100407 · Cited by 86
Arciuch, V. G. A., Russo, M. A., Dima, M., Kang, K. S., Dasrath, F., Liao, X.-H., Refetoff, S., Montagna, C., & Cristofano, A. D. (2011) · Oncotarget · doi:10.18632/oncotarget.380 · Cited by 85
Chen, Y., Chen, C., Riley, D. J., & Chen, P. (2011) · Cell Cycle · doi:10.4161/cc.10.4.14814 · Cited by 84
Crosstalk Between Bak/Bax and mTOR Signaling Regulates Radiation-Induced Autophagy
Moretti, L., Attia, A. A., Kim, K. W., & Lu, J. (2007) · Autophagy · doi:10.4161/auto.3607 · Cited by 84
Targeting the checkpoint kinase Chk1 in cancer therapy
Merry, C. R., Fu, K., Wang, J., Yeh, I., & Zhang, Y. (2010) · Cell Cycle · doi:10.4161/cc.9.2.10445 · Cited by 83
Targeting autophagy to fight hematopoietic malignancies
Puissant, A., Robert, G., & Auberger, P. (2010) · Cell Cycle · doi:10.4161/cc.9.17.13048 · Cited by 81
Wong, H. H., Vernillet, L., Peterson, A., Ware, J. A., Lee, L., Martini, J., Yu, P., Li, C., Rosario, G. D., Choo, E. F., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0445 · Cited by 81
Potential use of rapamycin in HIV infection
Donia, M., McCubrey, J. A., Bendtzen, K., & Nicoletti, F. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03735.x · Cited by 80
Self-citationKudchadkar, R. R., Paraiso, K. H. T., & Smalley, K. S. M. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e31824b436e · Cited by 80
Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA
Zhao, C. Y., Grinkevich, V., Nikulenkov, F., Bao, W., & Selivanova, G. (2010) · Cell Cycle · doi:10.4161/cc.9.9.11545 · Cited by 79
Cell cycle proteins in epithelial cell differentiation: Implications for breast cancer
Caldon, C. E., Sutherland, R. L., & Musgrove, E. A. (2010) · Cell Cycle · doi:10.4161/cc.9.10.11474 · Cited by 78
Heasman, S.-A., Zaitseva, L., Bowles, K. M., Rushworth, S. A., & MacEwan, D. J. (2011) · Oncotarget · doi:10.18632/oncotarget.321 · Cited by 77
Liu, Y., Fuchs, J. R., Li, C., & Lin, J. (2010) · Cell Cycle · doi:10.4161/cc.9.17.12946 · Cited by 72
FK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cells
Fruman, D. A., Wood, M. A., Gjertson, C. K., Katz, H. R., Burakoff, S. J., & Bierer, B. E. (1995) · European Journal of Immunology · doi:10.1002/eji.1830250239 · Cited by 72
The long unwinding road: XPB and XPD helicases in damaged DNA opening
Oksenych, V., & Coin, F. (2010) · Cell Cycle · doi:10.4161/cc.9.1.10267 · Cited by 72
Xu, C., Li, Y., Yue, P., Owonikoko, T. K., Ramalingam, S. S., Khuri, F. R., & Sun, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020899 · Cited by 72
MCL-1 localizes to sites of DNA damage and regulates DNA damage response
Jamil, S., Stoica, C., Hackett, T., & Duronio, V. (2010) · Cell Cycle · doi:10.4161/cc.9.14.12354 · Cited by 72
Regression of metastatic melanoma by targeting cancer stem cells
Schlaak, M., Schmidt, P., Bangard, C., Kurschat, P., Mauch, C., & Abken, H. (2012) · Oncotarget · doi:10.18632/oncotarget.437 · Cited by 71
Dunn, D., Dong, H., Yang, P., Johansen, M. J., Newman, R. A., & Lo, D. C. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07439.x · Cited by 71
Stauber, R. H., Knauer, S. K., Habtemichael, N., Bier, C., Unruhe, B., Weisheit, S., Spange, S., Nonnenmacher, F., Fetz, V., Ginter, T., et al. (2011) · Oncotarget · doi:10.18632/oncotarget.430 · Cited by 68
Bressanin, D., Evangelisti, C., Ricci, F., Tabellini, G., Chiarini, F., Tazzari, P. L., Melchionda, F., Buontempo, F., Pagliaro, P., Pession, A., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.579 · Cited by 68
Self-citationCurtailing side effects in chemotherapy: a tale of PKCδ in cisplatin treatment
Pabla, N., & Dong, Z. (2012) · Oncotarget · doi:10.18632/oncotarget.439 · Cited by 66
Ambs, S., & Glynn, S. A. (2011) · Cell Cycle · doi:10.4161/cc.10.4.14864 · Cited by 65
Choi, S., Gamper, A. M., White, J. S., & Bakkenist, C. J. (2010) · Cell Cycle · doi:10.4161/cc.9.20.13471 · Cited by 65
Mallon, R. G., Hollander, I. J., Feldberg, L. R., Lucas, J., Soloveva, V., Venkatesan, A. M., Dehnhardt, C. M., Santos, E. D., Chen, Z., dos Santos, O., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0954 · Cited by 65
Gubin, M. M., Calaluce, R., Davis, J. W., Magee, J., Strouse, C. S., Shaw, D. P., Ma, L., Brown, A., Hoffman, T. J., Rold, T. L., et al. (2010) · Cell Cycle · doi:10.4161/cc.9.16.12711 · Cited by 64
Mitotic DNA damage response: Polo-like Kinase-1 is dephosphorylated through ATM-Chk1 pathway
Lee, H. J., Hwang, H.-I., & Jang, Y. (2010) · Cell Cycle · doi:10.4161/cc.9.12.11904 · Cited by 64
McCubrey, J. A., Steelman, L. S., Abrams, S. L., Chappell, W. H., Russo, S. M., Ove, R., Milella, M., Tafuri, A., Lunghi, P., Bonati, A., et al. (2010) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210903282760 · Cited by 63
Self-citationDo predictive signatures really predict response to cancer chemotherapy?
Borst, P., & Wessels, L. F. A. (2010) · Cell Cycle · doi:10.4161/cc.9.24.14326 · Cited by 62
Burrows, N., Babur, M., Resch, J., Ridsdale, S., Mejin, M., Rowling, E. J., Brabant, G. E., & Williams, K. J. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1426 · Cited by 62
Liu, D., Xing, J., Trink, B., & Xing, M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25304 · Cited by 61
Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy
Rao, B., van Leeuwen, I. M. M., Higgins, M., Campbell, J., Thompson, A. M., Lane, D. P., & Laı́n, S. (2010) · Oncotarget · doi:10.18632/oncotarget.198 · Cited by 60
Castelló-Cros, R., Bonuccelli, G., Molchansky, A., Capozza, F., Witkiewicz, A. K., Birbe, R., Howell, A., Pestell, R. G., Whitaker‐Menezes, D., Sotgia, F., et al. (2011) · Cell Cycle · doi:10.4161/cc.10.12.16002 · Cited by 59
Mandal, M., Younes, M. N., Swan, E. A., et al. (2006) · Oral Oncology · doi:10.1016/j.oraloncology.2005.09.011 · Cited by 58
Raven, J. F., Williams, V., Wang, S., Tremblay, M. L., Muller, W. J., Durbin, J. E., & Koromilas, A. E. (2011) · Cell Cycle · doi:10.4161/cc.10.5.14956 · Cited by 58
Kandouz, M., Haïdara, K., Zhao, J., Brisson, M., & Batist, G. (2010) · Cell Cycle · doi:10.4161/cc.9.2.10505 · Cited by 57
Bao, W., Chen, M., Zhao, X., Kumar, R., Spinnler, C., Thullberg, M., Issaeva, N., Selivanova, G., & Strömblad, S. (2011) · Cell Cycle · doi:10.4161/cc.10.2.14538 · Cited by 56
Personalizing Therapy with Targeted Agents in Non-Small Cell Lung Cancer
Dienstmann, R., Martínez, P., & Felip, E. (2011) · Oncotarget · doi:10.18632/oncotarget.245 · Cited by 54
Falasca, M., Chiozzotto, D., Godage, H. Y., Mazzoletti, M., Riley, A. M., Previdi, S., Potter, B. V. L., Broggini, M., & Maffucci, T. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605408 · Cited by 54
McMahon, L. P., Yue, W., Santen, R. J., & Lawrence, J. C. (2004) · Molecular Endocrinology · doi:10.1210/me.2004-0305 · Cited by 53
Superoxide anions regulate TORC1 and its ability to bind Fpr1:rapamycin complex
Neklesa, T. K., & Davis, R. W. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807712105 · Cited by 53
Targeting translation in acute myeloid leukemia: A new paradigm for therapy?
Tamburini, J., Green, A. S., Chapuis, N., Bardet, V., Lacombe, C., Mayeux, P., & Bouscary, D. (2009) · Cell Cycle · doi:10.4161/cc.8.23.10091 · Cited by 53
Halicka, H. D., Zhao, H., Li, J., Traganos, F., Zhang, S., Lee, M., & Darzynkiewicz, Z. (2011) · Aging · doi:10.18632/aging.100397 · Cited by 53
APC/CCdc20targets E2F1 for degradation in prometaphase
Peart, M. J., Poyurovsky, M. V., Kass, E. M., Urist, M. J., Verschuren, E. W., Summers, M. K., Jackson, P. K., & Prives, C. L. (2010) · Cell Cycle · doi:10.4161/cc.9.19.13162 · Cited by 52
A phase I study of temsirolimus and metformin in advanced solid tumours
MacKenzie, M. J., Ernst, S., Johnson, C., & Winquist, E. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9570-8 · Cited by 52
Vucur, M., Roderburg, C., Bettermann, K., Tacke, F., Heikenwälder, M. F., Trautwein, C., & Luedde, T. (2010) · Oncotarget · doi:10.18632/oncotarget.170 · Cited by 52
Metformin and Cancer Stem Cells: Old Drug, New Targets
Bednar, F., & Simeone, D. M. (2012) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-12-0026 · Cited by 51
Mutations in the BRCT binding site of BRCA1 result in hyper-recombination
Dever, S. M., Golding, S. E., Rosenberg, E., Adams, B. R., Idowu, M. O., Quillin, J. M., Valerie, N. C. K., Xu, B., Povirk, L. F., & Valerie, K. C. (2011) · Aging · doi:10.18632/aging.100325 · Cited by 51
Tan, S., Ng, Y., & James, D. E. (2011) · Biochemical Journal · doi:10.1042/bj20110040 · Cited by 51
Will PI3K pathway inhibitors be effective as single agents in patients with cancer?
Garrett, J. T., Chakrabarty, A., & Arteaga, C. L. (2011) · Oncotarget · doi:10.18632/oncotarget.409 · Cited by 51
Forshell, L. P., Li, Y., Forshell, T. Z. P., Rudelius, M., Nilsson, L. M., Keller, U. B., & Nilsson, J. A. (2011) · Oncotarget · doi:10.18632/oncotarget.283 · Cited by 50
Tan, D. S.-W., Dumez, H., Olmos, D., Sandhu, S. K., Hoeben, A., Stephens, A. W., Poondru, S., Gedrich, R. W., Kaye, S. B., & Schöffski, P. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3006 · Cited by 50
Luchenko, V. L., Salcido, C. D., Zhang, Y., Agama, K., Komlódi-Pásztor, E., Murphy, R. F., Giaccone, G., Pommier, Y. G., Bates, S. E., & Varticovski, L. (2011) · Cell Cycle · doi:10.4161/cc.10.18.17190 · Cited by 49
Azmi, A. S., Banerjee, S., Ali, S., Wang, Z., Bao, B., Beck, F. W. J., Maitah, M., Choi, M., Shields, T. F., Philip, P. A., et al. (2011) · Oncotarget · doi:10.18632/oncotarget.269 · Cited by 48
Zhang, X. (2011) · Molecular Medicine Reports · doi:10.3892/mmr.2011.682 · Cited by 47
Laminin regulates PI3K basal localization and activation to sustain STAT5 activation
Xu, R., Spencer, V. A., Groesser, D. L., & Bissell, M. J. (2010) · Cell Cycle · doi:10.4161/cc.9.21.13578 · Cited by 47
Morelli, M. P., Tentler, J. J., Kulikowski, G. N., Tan, A. C., Bradshaw‐Pierce, E. L., Pitts, T. M., Brown, A. M., Nallapareddy, S., Arcaroli, J. J., Serkova, N. J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1507 · Cited by 46
Buchholz, B., Klanke, B., Schley, G., Bollag, G. E., Tsai, J. Y., Kroening, S., Yoshihara, D., Wallace, D. P., Kraenzlin, B., Gretz, N., et al. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr432 · Cited by 45
Detecting and targeting mesenchymal-like subpopulations within squamous cell carcinomas
Basu, D., Montone, K. T., Wang, L., Gimotty, P. A., Hammond, R., Diehl, J. A., Rustgi, A. K., Lee, J. T., Räsänen, K., Weinstein, G. S., et al. (2011) · Cell Cycle · doi:10.4161/cc.10.12.15883 · Cited by 44
From growing to secreting: New roles for mTOR in aging cells
Pani, G. (2011) · Cell Cycle · doi:10.4161/cc.10.15.16886 · Cited by 44
Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes
Cubillos‐Ruiz, J. R., Rutkowski, M. R., & Conejo-Garcia, J. R. (2010) · Cell Cycle · doi:10.4161/cc.9.2.10430 · Cited by 44
Targeting the Cancer Initiating Cell: The Ultimate Target for Cancer Therapy
McCubrey, J. A., Steelman, L. S., Abrams, S. L., Misaghian, N., Chappell, W. H., Mijatović, S., Montalto, G., Cervello, M., Laidler, P. M., Bonati, A., et al. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212799859701 · Cited by 44
Self-citationCusimano, A., Azzolina, A., Iovanna, J., et al. (2010) · Cell Cycle · doi:10.4161/cc.9.7.11254 · Cited by 43
Ricciardi, M. R., Scerpa, M. C., Bergamo, P., Ciuffreda, L., Petrucci, M. T., Chiaretti, S., Tavolaro, S., Mascolo, M. G., Abrams, S. L., Steelman, L. S., et al. (2012) · Journal of Molecular Medicine · doi:10.1007/s00109-012-0886-z · Cited by 43
Self-citationWawrousek, K., Fortini, B. K., Polaczek, P., Chen, L., Liu, Q., Dunphy, W. G., & Campbell, J. L. (2010) · Cell Cycle · doi:10.4161/cc.9.6.11049 · Cited by 42
Höglund, A., Strömvall, K., Li, Y., Forshell, L. P., & Nilsson, J. A. (2011) · Cell Cycle · doi:10.4161/cc.10.20.17887 · Cited by 41
A growing family: Adding mutated Erbb4 as a novel cancer target
Rudloff, U., & Samuels, Y. (2010) · Cell Cycle · doi:10.4161/cc.9.8.11239 · Cited by 41
Differences underlying EGFR and HER2 oncogene addiction
Faber, A. C., Wong, K., & Engelman, J. A. (2010) · Cell Cycle · doi:10.4161/cc.9.5.11096 · Cited by 41
Defective autophagy control by the p53 rheostat in cancer
Galluzzi, L., Morselli, E., Kepp, O., Maiuri, M. C., & Kroemer, G. (2010) · Cell Cycle · doi:10.4161/cc.9.2.10493 · Cited by 41
Lee, L., Niu, H., Rueger, R., Igawa, Y., Deutsch, J., Ishii, N., Mu, S., Sakamoto, Y., Busse‐Reid, R., Gimmi, C. D., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1696 · Cited by 41
Rieber, M., & RIEBER, M. S. (2005) · International Journal of Cancer · doi:10.1002/ijc.21478 · Cited by 41
Siu, A., Virtanen, C., & Jongstra, J. (2011) · Oncotarget · doi:10.18632/oncotarget.386 · Cited by 40
Martelli, A. M., Chiarini, F., Evangelisti, C., Ognibene, A., Bressanin, D., Billi, A. M., Manzoli, L., Cappellini, A., & McCubrey, J. A. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.694869 · Cited by 40
Self-citationGravina, G. L., Marampon, F., Petini, F., Biordi, L. A., Sherris, D., Jannini, E. A., Tombolini, V., & Festuccia, C. (2011) · Endocrine Related Cancer · doi:10.1530/erc-11-0045 · Cited by 40
Benefits of mTOR kinase targeting in oncology: pre-clinical evidence with AZD8055
Marshall, G. B., Howard, Z., Dry, J. R., Fenton, S. E., Heathcote, D., Gray, N. M., Keen, H. G., Logié, A., Holt, S. V., Smith, P. D., et al. (2011) · Biochemical Society Transactions · doi:10.1042/bst0390456 · Cited by 40
Characterization of human melanoma cell lines and melanocytes by proteome analysis
Caputo, E., Maiorana, L., Vasta, V., Pezzino, F. M., Sunkara, S., Wynne, K. J., Elia, G., Marincola, F. M., McCubrey, J. A., Libra, M., et al. (2011) · Cell Cycle · doi:10.4161/cc.10.17.17068 · Cited by 39
Self-citationModulated microtubule dynamics enable Hklp2/Kif15 to assemble bipolar spindles
Florian, S., & Mayer, T. U. (2011) · Cell Cycle · doi:10.4161/cc.10.20.17817 · Cited by 38
Guirouilh‐Barbat, J., Wilhelm, T., & López, B. S. (2010) · Oncotarget · doi:10.18632/oncotarget.203 · Cited by 38
Hu, Y., Spengler, M. L., Kuropatwinski, K. K., Comas, M., Jackson, M., Chernov, M. V., Gleiberman, A. S., Fedtsova, N. G., Rustum, Y. M., Gudkov, A. V., et al. (2011) · Oncotarget · doi:10.18632/oncotarget.411 · Cited by 37
Lehn, S., Fernö, M., Jirström, K., Rydén, L., & Landberg, G. (2011) · Cell Cycle · doi:10.4161/cc.10.6.15074 · Cited by 37
Substrate degradation by the anaphase promoting complex occurs during mitotic slippage
Lee, J., Kim, J. A., Margolis, R. L., & Fotedar, R. (2010) · Cell Cycle · doi:10.4161/cc.9.9.11519 · Cited by 37
Li, T., Wang, J., Wang, X., Yang, N. Y., Chen, S.-M., Tong, L., Yang, C., Meng, L., & Ding, J. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.167940 · Cited by 37
NEK11−Linking CHK1 and CDC25A in DNA damage checkpoint signaling
Sørensen, C. S., Melixetian, M. B., Klein, D. K., et al. (2010) · Cell Cycle · doi:10.4161/cc.9.3.10513 · Cited by 37
The TGFβ-Par6 polarity pathway: Linking the Par complex to EMT and breast cancer progression
Viloria‐Petit, A., & Wrana, J. L. (2010) · Cell Cycle · doi:10.4161/cc.9.4.10779 · Cited by 36
Chang, Q., Chapman, M. S., Miner, J. N., & Hedley, D. W. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-515 · Cited by 35
Lampiasi, N., Azzolina, A., Umezawa, K., Montalto, G., McCubrey, J. A., & Cervello, M. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.02.008 · Cited by 35
Self-citationSmith‐Roe, S. L., Patel, S. S., Simpson, D. A., Zhou, Y. C., Rao, S., Ibrahim, J. G., Kaiser‐Rogers, K. A., Cordeiro‐Stone, M., & Kaufmann, W. K. (2011) · Cell Cycle · doi:10.4161/cc.10.10.15613 · Cited by 35
The physiology and pathophysiology of rapamycin resistance: Implications for cancer
Gruppuso, P. A., Boylan, J. M., & Sanders, J. A. (2011) · Cell Cycle · doi:10.4161/cc.10.7.15230 · Cited by 34
BRCA1 modulates the expression of hnRNPA2B1 and KHSRP
Santarosa, M., Col, L. D., Viel, A., Bivi, N., DˈAmbrosio, C., Scaloni, A., Tell, G., & Maestro, R. (2010) · Cell Cycle · doi:10.4161/cc.9.23.14022 · Cited by 33
Dumont, F. J., Staruch, M. J., Grammer, T. C., Blenis, J., Kastner, C. A., & Rupprecht, K. M. (1995) · Cellular Immunology · doi:10.1006/cimm.1995.1100 · Cited by 33
Martelli, A. M., Papa, V., Tazzari, P. L., Ricci, F., Evangelisti, C., Chiarini, F., Grimaldi, C., Cappellini, A., Martinelli, G., Ottaviani, E., et al. (2010) · Leukemia · doi:10.1038/leu.2010.32 · Cited by 33
Self-citationAoki, K., Ogawa, T., Ito, Y., & Nakashima, S. (2004) · Oncology Reports · doi:10.3892/or.11.2.375 · Cited by 32
Tovar, C., Higgins, B., Deo, D. D., Kolinsky, K. D., Liu, J., Heimbrook, D. C., & Vassilev, L. T. (2010) · Cell Cycle · doi:10.4161/cc.9.16.12732 · Cited by 32
Coley, H. M., Hatzimichael, E. C., Blagden, S. P., McNeish, I. A., Thompson, A., Crook, T., & Syed, N. (2012) · Oncotarget · doi:10.18632/oncotarget.332 · Cited by 32
Exposure to acute hypoxia induces a transient DNA damage response which includes Chk1 and TLK1
Pires, I. M., Bencokova, Z., McGurk, C., & Hammond, E. M. (2010) · Cell Cycle · doi:10.4161/cc.9.13.12059 · Cited by 31
Chen, J., Shen, Q. “., Labow, M., & Gaither, L. A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3761 · Cited by 31
Falà, F., Blalock, W. L., Tazzari, P. L., Cappellini, A., Chiarini, F., Martinelli, G., Tafuri, A., McCubrey, J. A., Cocco, L., & Martelli, A. M. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.047639 · Cited by 31
Self-citationHerbert, B., Chanoux, R. A., Liu, Y., Baenziger, P. H., Goswami, C. P., McClintick, J. N., Edenberg, H. J., Pennington, R. E., Lipkin, S. M., & Kopelovich, L. (2010) · Oncotarget · doi:10.18632/oncotarget.175 · Cited by 30
STAT3, HIF-1, glucose addiction and Warburg effect
Darnell, J. E., Jr. (2010) · Aging · doi:10.18632/aging.100239 · Cited by 29
Baumann, P., Hagemeier, H., Mandl–Weber, S., Franke, D., & Schmidmaier, R. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328328d18b · Cited by 29
Revised genetic requirements for the decatenation G2 checkpoint: The role of ATM
Bower, J. J., Zhou, Y., Zhou, T., Simpson, D. A., Arlander, S. J. H., Paules, R. S., Cordeiro‐Stone, M., & Kaufmann, W. K. (2010) · Cell Cycle · doi:10.4161/cc.9.8.11470 · Cited by 29
Centrosomal Chk2 in DNA damage responses and cell cycle progession
Golan, A., Pick, E., Tsvetkov, L. M., Nadler, Y., Kluger, H. M., & Stern, D. F. (2010) · Cell Cycle · doi:10.4161/cc.9.13.12121 · Cited by 28
Normalizing a hyperactive mTOR initiates muscle growth during obesity
Williamson, D. L., & Drake, J. C. (2011) · Aging · doi:10.18632/aging.100290 · Cited by 26
Wiring the oncogenic circuitry: Pin1 unleashes mutant p53
Napoli, M., Girardini, J. E., Piazza, S., & Sal, G. D. (2011) · Oncotarget · doi:10.18632/oncotarget.329 · Cited by 25
Longoni, R., Spina, L., Vinci, S., & Acquas, E. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2192-9 · Cited by 25
Ribatti, D., Nico, B., Mangieri, D., Longo, V., Sansonno, D. E., Vacca, A., & Dammacco, F. (2007) · PubMed · doi:10.14670/hh-22.285 · Cited by 25
Major, P. (2011) · Aging · doi:10.18632/aging.100298 · Cited by 25
BRCA1 A-Complex fine tunes repair functions of BRCA1
Harris, J. L., & Khanna, K. K. (2011) · Aging · doi:10.18632/aging.100334 · Cited by 24
Protein phosphatase 1 regulators in DNA damage signaling
Küntziger, T. M., Landsverk, H. B., Collas, P., et al. (2011) · Cell Cycle · doi:10.4161/cc.10.9.15442 · Cited by 24
A Novel, Selective, and Efficacious Nanomolar Pyridopyrazinone Inhibitor of V600EBRAF
Whittaker, S. R., Ménard, D., Kirk, R., Ogilvie, L. M., Hedley, D., Zambon, A., Lopes, F., Preece, N., Manne, H. A., Rana, S., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1366 · Cited by 24
The beating heart of melanomas: a minor subset of cancer cells sustains tumor growth
Schmidt, P., & Abken, H. (2011) · Oncotarget · doi:10.18632/oncotarget.259 · Cited by 23
ΔNp63α promotes cellular quiescence via induction and activation of Notch3
Kent, S. S., Hutchinson, J. A., Balboni, A., DeCastro, A., Cherukuri, P., & DiRenzo, J. (2011) · Cell Cycle · doi:10.4161/cc.10.18.17300 · Cited by 22
Targeting Chk1 in the replicative stress response
Dai, Y., & Grant, S. (2010) · Cell Cycle · doi:10.4161/cc.9.6.11155 · Cited by 22
mTOR in podocyte function: Is rapamycin good for diabetic nephropathy?
Lu, M.-K., Gong, X., & Guan, K. (2011) · Cell Cycle · doi:10.4161/cc.10.20.17686 · Cited by 22
Piao, S., Lee, S., Xu, Y., Gwak, J., Oh, S., Park, B.-J., & Ha, N. (2011) · Cell Cycle · doi:10.4161/cc.10.3.14757 · Cited by 21
HdmX overexpression inhibits oncogene induced cellular senescence
Miller, K. R., Kelley, K. D., Tuttle, R., & Berberich, S. J. (2010) · Cell Cycle · doi:10.4161/cc.9.16.12779 · Cited by 21
Koomen, J. M., & Smalley, K. S. M. (2011) · Oncotarget · doi:10.18632/oncotarget.263 · Cited by 21
Wolff, R. A., Fuchs, M., Bartolomeo, M. D., Hossain, A. M., Stoffregen, C., Nicol, S. J., & Heinemann, V. (2011) · Cancer · doi:10.1002/cncr.26692 · Cited by 19
Targeting MEK is Effective Chemoprevention of Hepatocellular Carcinoma in TGF-α-Transgenic Mice
Wentz, S. C., Wu, H., Yip-Schneider, M., Hennig, M., Klein, P. J., Sebolt, J. S., & Schmidt, C. M. (2007) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-007-0396-4 · Cited by 19
Peddibhotla, S., Wei, Z., Papineni, R. V. L., Lam, M. H., Rosen, J. M., & Zhang, P. (2011) · Cell Cycle · doi:10.4161/cc.10.4.14901 · Cited by 19
PinX1: a sought-after major tumor suppressor at human chromosome 8p23
Zhou, X. Z. (2011) · Oncotarget · doi:10.18632/oncotarget.339 · Cited by 18
Vansteenkiste, J., Ramlau, R., von Pawel, J., Antonio, B. S., Eschbach, C., Szczęsna, A., Kennedy, L., Visseren‐Grul, C., Chouaki, N., & Reck, M. (2012) · Oncology · doi:10.1159/000335268 · Cited by 18
Defective autophagy associated with LC3 puncta in epothilone-resistant cancer cells
Shen, S., Kepp, O., Martins, I., Vitale, I., Souquère, S., Castedo, M., Pierron, G., & Kroemer, G. (2010) · Cell Cycle · doi:10.4161/cc.9.2.10468 · Cited by 17
Exploiting p53 Status to Enhance Effectiveness of Chemotherapy by Lowering Associated Toxicity
Steelman, L. S., Martelli, A. M., Nicoletti, F., & McCubrey, J. A. (2011) · Oncotarget · doi:10.18632/oncotarget.247 · Cited by 16
Self-citationAntiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future
Mulder, K. E., Koski, S. L., Scarfe, A. G., Chu, Q. S.-C., King, K. M., & Spratlin, J. L. (2010) · Oncotarget · doi:10.18632/oncotarget.187 · Cited by 16
Schuster, K., Zheng, J., Arbini, A., Zhang, C. C., & Scaglioni, P. P. (2011) · Blood Cancer Journal · doi:10.1038/bcj.2011.30 · Cited by 16
Inflammation and autophagy conspire to promote tumor growth
Körkaya, H., & Wicha, M. S. (2011) · Cell Cycle · doi:10.4161/cc.10.16.16414 · Cited by 15
Starved cells use mitochondria for autophagosome biogenesis
Rambold, A. S., & Lippincott‐Schwartz, J. (2010) · Cell Cycle · doi:10.4161/cc.9.18.13170 · Cited by 14
28th Annual JPMorgan Healthcare Conference--Exelixis and Nektar Therapeutics.
Gale, S., & Croasdell, G. (2010) · PubMed · Cited by 13
Cytokines shape chemotherapy-induced and ‘bystander' senescence
Hodný, Z., Hubáčková, S., & Bártek, J. (2010) · Aging · doi:10.18632/aging.100171 · Cited by 12
Musgrove, E. A., & Sutherland, R. L. (2010) · Cell Cycle · doi:10.4161/cc.9.23.13889 · Cited by 11
Autophagic tumor stroma: A biofuel for cancer growth
Iozzo, R. V. (2011) · Cell Cycle · doi:10.4161/cc.10.19.17124 · Cited by 7
Preoperative therapy for early-stage NSCLC: opportunities and challenges.
Owonikoko, T. K., Khuri, F. R., & Ramalingam, S. S. (2009) · PubMed · Cited by 4
Yu, X., Wang, H., Liu, S., Zhang, X., Guida, P. M., Hu, B., & Wang, Y. (2010) · Cell Cycle · doi:10.4161/cc.9.10.11651 · Cited by 3
Cited by
Wnt/β-catenin signaling in cancers and targeted therapies
Yu, F., Yu, C., Li, F., Zuo, Y., Wang, Y., Yao, L., Wu, C., Wang, C., & Ye, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00701-5 · Cited by 734
Kaufhold, S., & Bonavida, B. (2014) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/preaccept-1929235422128885 · Cited by 469
Shi, R., Wang, P.-Y., Li, X.-Y., Chen, J.-X., Li, Y., Zhang, X.-Z., Zhang, C.-G., Jiang, T., Li, W.-B., Ding, W., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4699 · Cited by 285
Targeting GSK3 and Associated Signaling Pathways Involved in Cancer
Duda, P., Akula, S. M., Abrams, S. L., Steelman, L. S., Martelli, A. M., Cocco, L., Ratti, S., Candido, S., Libra, M., Montalto, G., et al. (2020) · Cells · doi:10.3390/cells9051110 · Cited by 284
Self-citationMechanism-based cancer therapy: resistance to therapy, therapy for resistance
Ramos, P., & Bentires-Alj, M. (2015) · Oncogene · doi:10.1038/onc.2014.314 · Cited by 272
Metadata
- Authors
- McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Franklin, R. A., Montalto, G., Cervello, M., Libra, M., Candido, S., Malaponte, G., Mazzarino, M. C., Fagone, P., Nicoletti, F., Bäsecke, J., Mijatovic, S., Maksimovic-Ivanic, D., Milella, M., Tafuri, A., Chiarini, F., Evangelisti, C., Cocco, L., & Martelli, A. M.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2012-10-20
- Volume
- 3
- Issue
- 10
- Pages
- 1068-1111
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W1555772346
- Cited by
- 314
- References
- 356
- FWCI
- 14.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.